Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “buy” rating reissued by investment analysts at Stifel Nicolaus in a research note issued to investors on Friday, TipRanks reports.
A number of other equities research analysts have also commented on ATRA. Goldman Sachs Group lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their target price for the company from $14.00 to $9.00 in a research report on Friday, September 27th. ValuEngine upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Citigroup set a $14.00 target price on Atara Biotherapeutics and gave the company a “hold” rating in a research report on Monday, August 12th. Jefferies Financial Group lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $32.00 to $15.00 in a research report on Monday, September 16th. Finally, Mizuho set a $43.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a research report on Wednesday, September 18th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. Atara Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $29.75.
Shares of ATRA stock traded down $0.01 during trading hours on Friday, reaching $12.28. 35,082 shares of the company’s stock were exchanged, compared to its average volume of 720,720. The stock’s fifty day moving average price is $13.93 and its two-hundred day moving average price is $19.79. The stock has a market cap of $681.65 million, a PE ratio of -2.33 and a beta of 2.09. Atara Biotherapeutics has a 1 year low of $11.50 and a 1 year high of $43.94. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.06.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.45) by ($0.15). On average, equities analysts expect that Atara Biotherapeutics will post -5.71 EPS for the current fiscal year.
In other Atara Biotherapeutics news, insider Joe Newell sold 3,500 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $13.51, for a total value of $47,285.00. Following the sale, the insider now owns 57,998 shares in the company, valued at approximately $783,552.98. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers raised its stake in shares of Atara Biotherapeutics by 10.3% during the 3rd quarter. Rhumbline Advisers now owns 68,067 shares of the biotechnology company’s stock worth $961,000 after buying an additional 6,332 shares during the period. Alberta Investment Management Corp raised its stake in Atara Biotherapeutics by 39.8% in the 3rd quarter. Alberta Investment Management Corp now owns 362,030 shares of the biotechnology company’s stock valued at $5,112,000 after purchasing an additional 103,100 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Atara Biotherapeutics by 59.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,010 shares during the last quarter. Maverick Capital Ltd. raised its stake in Atara Biotherapeutics by 156.4% in the 2nd quarter. Maverick Capital Ltd. now owns 2,232,476 shares of the biotechnology company’s stock valued at $44,895,000 after purchasing an additional 1,361,712 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at $266,000. 91.78% of the stock is owned by institutional investors and hedge funds.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
See Also: Technical Analysis
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.